Overview

Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer

Status:
Completed

Trial end date:
2006-01-01

Target enrollment:

Participant gender:

Summary

The objective is to evaluate the toxicity profile, response rate, and time to progression of Cetuximab administered in combination with either Carboplatin + Gemcitabine in patients with advanced non-small cell lung cancer with positive EGFr expression.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Alabama at Birmingham

Collaborators:

Eli Lilly and Company
ImClone LLC

Treatments:

Antibodies
Carboplatin
Cetuximab
Gemcitabine
Mitogens